Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 93Carcinoma, Non-Small-Cell Lung 46Neoplasms 33Carcinoma, Renal Cell 24Neoplasm Metastasis 16Colorectal Neoplasms 13Carcinoma, Hepatocellular 12Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Advanced Cancer 9Squamous Cell Carcinoma of Head and Neck 8Uveal Melanoma 7Stomach Neoplasms 7Skin Neoplasms 7Mesothelioma 7Kidney Neoplasms 7Carcinoma, Transitional Cell 7Recurrence 6Pancreatic Neoplasms 6Liver Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Solid Tumor 4

Interventions

spartalizumab 2pazopanib 2carotuximab 2belinostat 2balstilimab 2Ipilimumab 2Doxorubicin 2soblidotin 1TTI-621 1Injections 1Imatinib Mesylate 1Ifosfamide 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hemangiosarcoma × Ipilimumab × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT04607200 2022-01-11

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Agenus Inc.

Phase 2 Withdrawn
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡